For example, PPARα-dependent hepatocarcinogenesis has been reported in chronic rodent models [74], and PPARα agonists have been found to attenuate cell growth and angiogenesis in various tumor strains including A459 human non-small cell lung cancer, B16-F10 murine melanoma, Lewis lung carcinoma, U87 human glioblastoma, and HT-1080 human fibrosarcoma [75,76]. This evidence concerns the gene PPARA and melanoma.